Michael S. Boosalis
Papers
1
Total Citations
27
H-Index
1
About
Michael S. Boosalis is a leading translational researcher in hematology, whose work focuses on developing novel therapies for beta-hemoglobinopathies such as sickle cell disease and beta-thalassemia. His primary research areas include fetal globin gene reactivation, high-throughput drug screening, and in vivo preclinical models. Boosalis made a major contribution by pioneering a high-throughput screening (HTS) approach using a LCR-γ-globin promoter-GFP reporter assay to identify small-molecule inducers of fetal hemoglobin. His landmark 2015 study, cited 27 times, demonstrated that novel compounds identified through this robotic system were active in vivo in anemic baboons and transgenic mice, offering a promising path toward safe, orally-bioavailable therapies. This work has significant impact, as reactivating fetal globin can dramatically reduce disease severity in patients. Boosalis’s achievements include bridging the gap between in vitro discovery and preclinical validation, establishing a robust pipeline for drug development. His research continues to inspire efforts to translate these findings into clinical treatments, potentially benefiting millions worldwide.
Research Focus
Key Achievements
Top Papers
- 1